Analysts expect that Walgreens Boots Alliance Inc (NASDAQ:WBA) will post $30.37 billion in sales for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Walgreens Boots Alliance’s earnings, with the highest sales estimate coming in at $30.89 billion and the lowest estimate coming in at $29.57 billion. Walgreens Boots Alliance reported sales of $28.50 billion during the same quarter last year, which would suggest a positive year over year growth rate of 6.6%. The business is scheduled to issue its next earnings results before the market opens on Thursday, January 4th.
According to Zacks, analysts expect that Walgreens Boots Alliance will report full year sales of $30.37 billion for the current year, with estimates ranging from $123.89 billion to $133.29 billion. For the next year, analysts anticipate that the business will report sales of $136.32 billion per share, with estimates ranging from $127.83 billion to $144.97 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Walgreens Boots Alliance.
Walgreens Boots Alliance (NASDAQ:WBA) last announced its quarterly earnings results on Wednesday, October 25th. The pharmacy operator reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.10. The company had revenue of $30.15 billion for the quarter, compared to the consensus estimate of $29.93 billion. Walgreens Boots Alliance had a return on equity of 18.36% and a net margin of 3.45%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $1.07 EPS.
In related news, Director William C. Foote sold 2,736 shares of Walgreens Boots Alliance stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $67.37, for a total value of $184,324.32. Following the sale, the director now directly owns 16,415 shares in the company, valued at approximately $1,105,878.55. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Anthony Lederer acquired 20,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The stock was purchased at an average price of $67.00 per share, for a total transaction of $1,340,000.00. Following the completion of the acquisition, the director now owns 50,000 shares in the company, valued at approximately $3,350,000. The disclosure for this purchase can be found here. 14.80% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Hudock Capital Group LLC lifted its stake in Walgreens Boots Alliance by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,306 shares of the pharmacy operator’s stock worth $102,000 after purchasing an additional 6 shares in the last quarter. Westside Investment Management Inc. lifted its stake in Walgreens Boots Alliance by 10.4% in the 2nd quarter. Westside Investment Management Inc. now owns 1,325 shares of the pharmacy operator’s stock worth $102,000 after purchasing an additional 125 shares in the last quarter. Zions Bancorporation lifted its stake in Walgreens Boots Alliance by 983.3% in the 3rd quarter. Zions Bancorporation now owns 1,365 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,239 shares in the last quarter. IHT Wealth Management LLC lifted its stake in Walgreens Boots Alliance by 46.3% in the 2nd quarter. IHT Wealth Management LLC now owns 6,946 shares of the pharmacy operator’s stock worth $135,000 after purchasing an additional 2,199 shares in the last quarter. Finally, Bristlecone Advisors LLC purchased a new position in Walgreens Boots Alliance in the 3rd quarter worth approximately $135,000. Institutional investors own 61.18% of the company’s stock.
Shares of Walgreens Boots Alliance (NASDAQ WBA) traded down $0.11 on Tuesday, reaching $72.44. The company’s stock had a trading volume of 2,358,980 shares, compared to its average volume of 5,504,214. The firm has a market cap of $71,246.20, a P/E ratio of 14.11, a P/E/G ratio of 1.28 and a beta of 1.22. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.07 and a quick ratio of 0.59. Walgreens Boots Alliance has a 12 month low of $63.82 and a 12 month high of $88.00.
Walgreens Boots Alliance announced that its board has approved a share buyback plan on Wednesday, October 25th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the pharmacy operator to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Monday, November 13th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.21%. The ex-dividend date was Friday, November 10th. Walgreens Boots Alliance’s dividend payout ratio (DPR) is presently 42.33%.
COPYRIGHT VIOLATION NOTICE: “Walgreens Boots Alliance Inc (WBA) Expected to Post Quarterly Sales of $30.37 Billion” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/19/walgreens-boots-alliance-inc-wba-expected-to-post-quarterly-sales-of-30-37-billion.html.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.